郑州大小眼矫正(郑州近视手术的眼科医院) (今日更新中)

The FDA announced on Friday that it has issued an emergency use authorization for a second coronavirus vaccine. Its approval comes just one week after the FDA gave an emergency use authorization for a similar vaccine by Pfizer. That vaccine began distribution earlier this week. Moderna’s vaccine has been hailed as a medical breakthrough. The vaccine has been considered 94.1% effective against the virus. According to Moderna, none of the thousands who were given two shots of the vaccine had severe COVID-19 symptoms. That is compared to 30 patients who were given a placebo who had symptoms.In order to obtain an emergency use authorization, the FDA weighed the vaccine’s benefits against possible side effects. An emergency use authorization is not a full FDA approval, but it allows those outside of a clinical or hospital setting to obtain the vaccine. “With the availability of two vaccines now for the prevention of COVID-19, the FDA has taken another crucial step in the fight against this global pandemic that is causing vast numbers of hospitalizations and deaths in the United States each day,” FDA Commissioner Stephen M. Hahn said in a statement. “Through the FDA’s open and transparent scientific review process, two COVID-19 vaccines have been authorized in an expedited timeframe while adhering to the rigorous standards for safety, effectiveness, and manufacturing quality needed to support emergency use authorization that the American people have come to expect from the FDA. These standards and our review process, which are the same we have used in reviewing the first COVID-19 vaccine and intend to use for any other COVID-19 vaccines, included input from independent scientific and public health experts as well as a thorough analysis of the data by the agency’s career staff.”According to Moderna, approximately 20 million doses will be delivered to the U.S. government by the end of December 2020. Moderna said it expects to have between 100 million and 125 million doses available globally in the first quarter of 2021, with 85-100 million of those available in the U.S.While the vaccine could nearly eliminate the number of hospitalizations and deaths associated with the virus, the shot might result in some symptoms.In an interview with CNN last month, Operation Warp Speed chief scientific adviser Moncef Slaoui said that 10 to 15% of those immunized had noticeable side effects.“Most people will have much less noticeable side effects. That frankly -- in comparison to a 95% protection against an infection that can be deadly or significantly debilitating -- I think is an appropriate balance," he told CNN. 2648

The CEO of a skincare company has issued an apology after she accused a man of "defacing private property" by chalking the words "Black Lives Matter" on the building where he lives in San Francisco.The CEO of LAFACE skincare, Lisa Alexander, issued a public apology to James Juanillo, the man she accosted."The last 48 hours has taught me that my actions were those of someone who is not aware of the damage caused by being ignorant and naive to racial inequalities. When I watch the video I am shocked and sad that I behaved the way I did. It was disrespectful to Mr. Juanillo and I am deeply sorry for that," Alexander's statement read, in part.The video, posted to social media on Friday, shows Alexander and another man, later identified as Robert Larkin, speaking with Juanillo. In the video, Alexander accuses Juanillo of "defacing private property" as he stenciled "Black Lives Matter" in yellow chalk on a wall at his home.Alexander and Larkin told Jaunillo that he was "free to express his opinion," but "that was not the way to do it."Juanillo then asked if it would be OK if he were chalking his own property. Alexander and Larkin said that they knew Juanillo didn't own the property because they "knew who lived there."Juanillo encouraged Alexander and Larkin to call the police if they felt unsafe. Juanillo told KGO in San Francisco that the two did call the police, but when officers arrived, they quickly recognized Juanillo as a resident."I didn't even show (the police) my ID," Juanillo told KGO.KGO also spoke to one of the property owners, who said he does not know Alexander or Larkin.The video of the incident spread quickly on social media, with many referring to Alexander as a "Karen" — a slang term for an entitled woman, often used in the context of racism.Alexander's identity was not independently confirmed until she came forward to apologize. However, Birchbox — a makeup subscription service — released a statement on Twitter denouncing Alexander's actions after Twitter users brought the video to their attention. Birchbox said that it had not worked with LAFACE in "several years," but nonetheless had "officially cut ties with the company."The video also prompted trolls to leave negative Yelp reviews of a Los Angeles-based skincare store, My LA Face, which has no connection to Alexander or her business, LAFACE. A representative for Yelp told KGO that those negative reviews would be removed.Read Alexander's full statement below.I want to apologize directly to Mr. Juanillo. There are not enough words to describe how truly sorry I am for being disrespectful to him last Tuesday when I made the decision to question him about what he was doing in front of his home. I should have minded my own business.The last 48 hours has taught me that my actions were those of someone who is not aware of the damage caused by being ignorant and naive to racial inequalities. When I watch the video I am shocked and sad that I behaved the way I did. It was disrespectful to Mr. Juanillo and I am deeply sorry for that. I did not realize at the time that my actions were racist and have learned a painful lesson. I am taking a hard look at the meaning behind white privilege and am committed to growing from this experience. I would love to have coffee with Mr. Juanillo in our neighborhood so I can apologize in person and share a dialogue where I can continue to learn and grow and be a better person.Robert Larkin also issued an apology statement.Over the last two days, I have had my eyes opened wide to my own ignorance of racial inequity, and I have thought a lot about my own personal blind spots. I was wrong to question Mr. Juanillo, and I was wrong to call the neighborhood police watch. It was wrong, and I am profoundly sorry for treating him with disrespect.I have a lot to learn about how racism impacts people in their lives, daily, I have hurt my neighbor. I am full of regret and very sorry. I am hoping to meet with him soon to express my sincere apology and to ask for his forgiveness and guidance in helping me begin the journey towards being a kinder, more thoughtful and sensitive person. 4144

The Food and Drug Administration released updated safety standards Tuesday for makers of COVID-19 vaccines despite efforts by the White House to block them, clearing the way for requirements that are widely expected to prevent the introduction of a vaccine before Election Day.In the new guidelines posted on its website, the FDA said vaccine makers should follow trial participants for at least two months to rule out any major side effects before seeking emergency approval. That standard had been a sticking point between the FDA and White House officials, who said it could unreasonably delay the availability of COVID-19 vaccines.President Donald Trump has repeatedly insisted a vaccine could be authorized before Nov. 3, even though top government scientists working on the effort have said that timeline is very unlikely. On Monday Trump said vaccines are coming “momentarily,” in a video recorded after he returned to the White House.Former FDA officials have warned that public perception that a vaccine was being rushed out for political reasons could derail efforts to vaccinate millions of Americans.A senior administration official confirmed Monday that the White House had blocked FDA’s plans to formally publish the safety guidelines based on the two-month data requirement, arguing there was “no clinical or medical reason” for it.But on Tuesday, the FDA posted the guidance on its website, making clear that regulators plan to impose the safety standards for any vaccine seeking an expedited path to market.FDA Commissioner Stephen Hahn said in a statement that he hoped the guidelines would help “the public understand our science-based decision-making process that assures vaccine quality, safety and efficacy.”The requirements are aimed at companies seeking rapid approval through the FDA’s emergency authorization pathway. That accelerated process, reserved for health emergencies, allows medical products onto the market based on a lower bar than traditional FDA approval. But FDA has made clear only vaccines that are shown to be safe and effective will be authorized for coronavirus.Former FDA acting commissioner Dr. Stephen Ostroff said the requirements seem reasonable given the agency is in largely “uncharted territory” in terms of considering emergency use of a vaccine. The agency has only previously cleared one vaccine through the method — a decades-old shot that was authorized to prevent anthrax poisoning in 2005.“There really is no margin for error here,” Ostroff said. “Even when you’re talking about limited use of a vaccine there has to be some level of assurance that there isn’t a risk here that would far outweigh the benefit.”Dr. Peter Marks, the head of FDA’s vaccine division, said Tuesday that the two-month follow-up requirement was chosen to be “something reasonably aggressive, but not too conservative — right in the middle.” He spoke at a symposium organized by Johns Hopkins University.Initial doses of vaccines for emergency use would likely be reserved for medical workers and people with health conditions that make them particularly vulnerable to coronavirus. Full FDA approval for the general population will require significantly more data and is not expected until mid-2021.The White House attempt to block the guidance followed a string of instances in which the Trump administration has undercut its own medical experts working to combat the pandemic. FDA’s Hahn has been attempting to shore up public confidence in the vaccine review process for weeks, vowing that career scientists, not politicians, will decide if the shots are safe and effective.Pfizer CEO Albert Bourla has stoked excitement by saying that he expects data on whether the company’s candidate works to be ready in late October. But a number of variables would still have to align for the company to submit, and the FDA to review and greenlight, a vaccine application before Nov. 3. Pfizer’s competitors Moderna, AstraZeneca and Johnson & Johnson are working on longer research timelines.Vaccine development typically takes years, but the U.S. government has invested billions in efforts to accelerate the process and help multiple drugmakers prepare multiple candidates. All the doses will be purchased by the federal government for use vaccinating the U.S. population.Beyond exposing the rift between the White House and FDA, the delay in releasing the guidelines may have had limited practical effect.FDA scientists have been discussing the guidelines publicly for weeks and have made clear that the recommendations have already been shared with each of the vaccine developers.Former FDA Commissioner Scott Gottlieb said Tuesday that drugmakers depend on the FDA’s science-based endorsement to vouch for the safety and effectiveness of their products.“I can’t imagine a circumstance where a sponsor would challenge or seek to undermine the FDA’s role here,” Gottlieb said at the COVID-19 symposium. “This is precisely the moment when we need an objective, neutral arbiter.”Last week, Gottlieb and six other former FDA commissioners blasted the Trump administration for “undermining the credibility” of the agency in a op-ed calling for the release of the then-stalled vaccine guidelines.“Scientists should make decisions based on data, unfettered by political pressure or the intrusions of ideology or vested interests,” the officials wrote.___AP Medical Writer Lauran Neergaard contributed to this report.___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content. 5644

The College Football Playoff semifinal at the Rose Bowl is moving to AT&T Stadium in Arlington, Texas.Bill Hancock, executive director of the College Football Playoff, made the announcement in a statement Saturday night on the eve of the release of the final playoff rankings.The College Football Playoff and Rose Bowl "mutually agreed" to move the game because of the growing number of coronavirus cases in Southern California."We are pleased that parents and loved ones will now be able to see their students play in the game," Hancock said.The move came after several coaches expressed their dismay about possibly traveling to the Rose Bowl to play in a game where players' families wouldn't be allowed.Los Angeles County is under a stay-at-home order that took effect earlier this month. Pasadena, home to the Rose Bowl, has its own public health department but has mostly followed the county's practices during the pandemic.A source told The Associated Press that the Rose Bowl sought an exemption from the state of California to allow families to attend but was denied twice.Hancock said the game will still be played in the mid-afternoon on New Year's Day."We are very grateful to Rose Bowl officials and the city of Pasadena," Hancock said. "They have worked hard to listen to the concerns of the CFP, the teams that might have played there, and their state and government officials. The Tournament of Roses has acted in the best interest of the people who live in Southern California, and we're grateful to Cotton Bowl and AT&T Stadium officials for their ability to make this late switch possible." 1624

The Collective Brewing project has teamed up with Lone Star Taps and Caps in Fort Worth, Texas to turn Easter's most polarizing treat—Marshmallow Peeps—into a craft beer. They plan to tap the concoction Friday, March 30 at 6 p.m. at the Taproom in Fort Worth, and they're calling the collaboration "Peep this Collab."On the website, the taste is described as tart and lemon-y and the look is described as a glitter bomb with fabulous sparkle. However, Ryan Deyo, Collective Brewing's head brewer and co-founder said drinkers could expect a "lightly tart" and marshmallow-y" taste from the beer on guidelive.Regardless of the flavor, Deyo said they mashed 30 boxes of peeps into a beer brewed with sour ale, vanilla and butterfly pea flowers (yes, actual flowers). If that doesn't sound delicious already, the beer will have purple tint thanks to the pea flowers and they will have edible glitter to up the sparkle content. This whole idea is a part of Deyo's passion to make beer for more fun."I've been on a kick to assert beer should be a fun thing," Deyo told guidelive. "We make a beer with ramen noodles, so Peeps isn't really a stretch."If Ramen Noodle beer sound just as good as peep beer, you're in luck, but neither of those flavors top the wackiest ever made by craft brewers. Flavors like Rocky Mountain Oyster, Oyster, Coconut Curry and Pizza beer have turned heads in the past.  1439

来源：资阳报